Estrogen and progesterone receptors (ER/PRs) are nuclear IHC biomarkers that define hormone-receptor-positive breast cancers and determine eligibility for endocrine treatments such as tamoxifen, aromatase inhibitors, or fulvestrant [55,75]. Here, PGR is linked to breast carcinoma.